Summary & Overview

HCPCS Level II J3262: Tocilizumab Injection, 1 mg

HCPCS Level II code J3262 designates a 1 mg injectable unit of tocilizumab, a monoclonal antibody used in multiple inflammatory and immune-mediated conditions. Nationally, accurate reporting of unit-based HCPCS drug codes is critical for drug utilization tracking, reimbursement accuracy, and clinical inventory management given the high cost and weight-based dosing of many biologics. This publication analyzes coverage and billing considerations for major national payers.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, typical billing practices for unit-dosed injectable biologics, and common modifiers used in practice. The report also outlines clinical context for tocilizumab administration and where to expect site-of-service billing (outpatient infusion centers, physician offices, and hospital outpatient departments).

The content provides benchmarks and practical insights into service line implications, claims processing nuances for HCPCS Level II drug codes, and considerations for coding unit-based injectable biologics. Data not available in the input for some payer-specific policy details or utilization metrics is noted in relevant sections.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ3262HCPCS Level IItocilizumabinjectable biologicdrug administrationinfusion servicesoutpatient billingmedication coding

Billing Code Overview

HCPCS Level II code J3262 represents Injection, tocilizumab, 1 mg. This code is used to report the drug-to-patient unit of tocilizumab administered by injection. The service type is medication administration (injectable biologic). The typical site of service for billing this HCPCS Level II code is outpatient infusion or injection settings, including hospital outpatient departments, physician offices, infusion centers, and ambulatory care clinics.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with moderate to severe rheumatoid arthritis or giant cell arteritis who requires intravenous or subcutaneous administration of tocilizumab for control of systemic inflammation after inadequate response to conventional disease-modifying antirheumatic drugs. The patient presents to an infusion center, rheumatology clinic, or outpatient pharmacy clinic for dosing. Clinical workflow includes pre-infusion nursing assessment (vital signs, review of recent labs including CBC, liver function tests, and CRP/ESR), verification of the tocilizumab order (dose calculated in mg/kg or fixed dosing), pharmacy preparation of the sterile injectable product, and administration by an authorized clinician or infusion nurse. Post-injection monitoring for infusion reactions or hypersensitivity is performed for a period determined by facility protocol. Documentation includes the administered HCPCS Level II code J3262 (tocilizumab, 1 mg), lot number, expiration, route, dose administered, site of service, supervising provider, and any immediate adverse events.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/amount used	Use when a portion of a single-use vial is discarded after administration and payor requires reporting of wasted drug.
`JZ`	No drug discarded/entire amount administered	Use when the full vial contents were administered and no waste occurred.
`59`	Distinct procedural service	Use when a separately identifiable service or procedure (unrelated to the infusion) is performed on the same date.
`76`	Repeat procedure by same physician	Use when an identical injection/service is repeated by same provider the same day.
`77`	Repeat procedure by another physician	Use when repeated by a different provider the same day (note: not in provided list; excluded).
`62`	Two surgeons	Not typically applicable to infusion; reserved for concurrent surgeon billing (included here only if surgical co-surgeon is present).
`52`	Reduced services	Use when a billed service is partially reduced or not completed as originally planned.
`53`	Discontinued procedure	Use when the infusion or administration was started but discontinued due to adverse event.
`76`	Duplicate entry (already listed)	Duplicate removed in table.
`KX`	Medical necessity requirements met	Use when documentation supports that specific medical necessity edits are met per payer policy.
`GZ`	Item/service expected to be denied as not reasonable/necessary	Use when payer-required advance determination of medical necessity is not complete and provider asserts service was necessary.
`AA`	Anesthesia by anesthesiologist	Not in provided list; excluded.

Taxonomy Code	Specialty	Notes
`207R00000X`	Rheumatology	Rheumatologists diagnose and manage conditions (e.g., RA) that commonly use tocilizumab.
`163WL0400X`	Allergy & Immunology	Specialists may use tocilizumab for certain inflammatory or immune-mediated conditions.
`261QM0700X`	Hematology/Oncology	Hematology/oncology may administer tocilizumab for cytokine release syndrome in CAR-T therapy contexts.
`251B00000X`	Internal Medicine	Hospitalists and internists may coordinate infusions in inpatient or outpatient settings.
`363L00000X`	Nurse Practitioner	Advanced practice providers frequently perform assessment and order/coordinate administration.

Note: Only the most clinically relevant modifiers from the provided list are selected and presented with standard CMS meanings and typical use-cases for injectable biologic administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M05.79`	Rheumatoid arthritis with rheumatoid factor, multiple sites, without organ or systems involvement	Tocilizumab is indicated for moderate to severe rheumatoid arthritis when prior DMARDs were inadequate.
`M06.9`	Rheumatoid arthritis, unspecified	Common diagnosis prompting biologic therapy including tocilizumab when disease activity persists.
`M31.6`	Giant cell arteritis with polymyalgia rheumatica	Tocilizumab is approved for giant cell arteritis to reduce relapse and steroid exposure.
`M35.3`	Polymyalgia rheumatica	Tocilizumab may be used off-label or in selected refractory cases to manage inflammatory symptoms.
`D89.89`	Other specified immunological disorders	Tocilizumab can be used in selected immune-mediated conditions per specialist guidance.
`T80.7XXA`	Infection following infusion, initial encounter	Documentation of adverse infusion-related infections when they occur; relevant for post-administration coding.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	May be billed for intravenous administration time when tocilizumab is given as an IV infusion and infusion time and monitoring meet payer criteria.
`96415`	Each additional hour (chemotherapy infusion)	Billed when infusion time exceeds initial hour and documentation supports extended IV infusion and monitoring.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used when tocilizumab is administered subcutaneously in a clinic setting.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, low to moderate complexity	May be used for pre-injection evaluation or follow-up visit related to ongoing therapy management.
`99070`	Supplies and materials (except for commonly included items)	Use when additional supplies required for preparation/administration are billed separately under payer rules.